Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Reuters

11/13

Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Overview

Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations
Company's operating expenses increased to $42.8 mln in Q3 2025
Celcuity on track to submit NDA for gedatolisib in Q4 2025

Outlook

Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026
Celcuity plans to submit NDA for gedatolisib in Q4 2025

Result Drivers

FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Adjusted EPS	Beat	-$0.78	-$1.02 (7 Analysts)
Q3 EPS		-$0.92
Q3 Adjusted Net Income	Beat	-$37.20 mln	-$43 mln (7 Analysts)
Q3 Net Income		-$43.80 mln
Q3 Operating Expenses		$42.80 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17

Press Release: ID:nGNX9HLwC2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583588271"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583588271\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583588271?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583588271","market":"us","top_or_hot":-1,"title":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share </title></head><body><p><span>Overview</span></p><ul><li><p>Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations</p></li><li><p>Company's operating expenses increased to $42.8 mln in Q3 2025</p></li><li><p>Celcuity on track to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Outlook</span></p><ul><li><p>Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Celcuity plans to submit NDA for gedatolisib in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Adjusted EPS</p></td><td><p>Beat</p></td><td><p>-$0.78</p></td><td><p>-$1.02 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.92</p></td><td></td></tr><tr><td><p>Q3 Adjusted Net Income</p></td><td><p>Beat</p></td><td><p>-$37.20 mln</p></td><td><p>-$43 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$43.80 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$42.80 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/CELC\">Celcuity Inc</a> is $78.00, about 1.5% below its November 11 closing price of $79.17</p></li></ul><p>Press Release: <span>ID:nGNX9HLwC2</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CELC","symbol_name":"Celcuity Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO12O:1","article_id":"2583588271","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583588271","pubTimestamp":1762981905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per shareOverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating ex","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CELC":"Celcuity Inc","BK4139":"生物科技"},"translate_title":"癌症诊断公司Celcuity公布第三季度调整后每股亏损低于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share OverviewCelcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectationsCompany's operating expenses increased to $42.8 mln in Q3 2025Celcuity on track to submit NDA for gedatolisib in Q4 2025OutlookCelcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026Celcuity plans to submit NDA for gedatolisib in Q4 2025Result DriversFINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structureKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Adjusted EPSBeat-$0.78-$1.02 (7 Analysts)Q3 EPS-$0.92Q3 Adjusted Net IncomeBeat-$37.20 mln-$43 mln (7 Analysts)Q3 Net Income-$43.80 mlnQ3 Operating Expenses$42.80 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17Press Release: ID:nGNX9HLwC2For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}